Bristol Myers Squibb Aligns MTAP Precision Oncology Push With Solar Shift

robot
Abstract generation in progress

Bristol Myers Squibb (NYSE:BMY) has announced an expanded collaboration with Foundation Medicine for a next-generation sequencing companion diagnostic to identify patients with homozygous MTAP deletion, advancing its precision oncology initiatives. Concurrently, the company committed to sourcing 145 MW of solar power from Geronimo Power’s Blevins Solar Project as part of its sustainability efforts. These dual advancements in scientific and ESG priorities come as BMY’s stock has seen significant gains, up 10.0% year-to-date and 27.2% over the past year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin